Please note, this OEL/ADE monograph also applies to momelotinib dihydrochloride (CAS RN 1380317-28-1). Momelotinib, previously known as CYT387, is a potent and selective small-molecule inhibitor of Janus kinase (JAK)1 and JAK2 enzymes and of activin receptor type-1 (ACVR1)/activin receptor-like kinase-2 (ALK2). It is in development for the treatment of myelofibrosis (MF) in symptomatic, anemic patients previously treated with an approved JAK inhibitor. Momelotinib is also under investigation for the oral treatment of pancreatic cancer, nonsmall cell lung cancer, and myeloproliferative disorders (including MF, essential thrombocythemia, polycythemia vera, primary myelofibrosis (PMF)).
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Momelotinib, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.